Marchetti, M
Barosi, G
Cervantes, F
Birgegård, G
Griesshammer, M
Harrison, C
Hehlmann, R
Kiladjian, J-J
Kröger, N
McMullin, M F
Passamonti, F
Vannucchi, A
Barbui, T
Article History
Received: 3 August 2016
Revised: 27 August 2016
Accepted: 14 September 2016
First Online: 14 October 2016
Competing interests
: Dr Barosi participated in speakers’ bureau for Novartis. Dr Kiladjian’s research was funded by Novartis and AOP Orphan; he also participated in speakers’ bureau for Novartis and AOP Orphan. Dr Passamonti participated in speakers’ bureau for Novartis. Dr Griesshammer received travel reimbursement from Novartis and Shire, participated in speakers’ bureaus for Baxalta, AOP Orphan, Novartis and Shire and received honoraria from Baxalta, AOP Orphan, Novartis and Shire. Dr Vannucchi participated in advisory boards and speakers’ bureaus for Novartis. Dr Kröeger received honorarium and research funding from Novartis. Dr McMullin received speaker fee from Novartis and Shire. Dr Harrison received research support from Novartis and honoraria from Baxalta, Novartis, Sanofi and Shire; she joined speakers’ bureaus for Baxalta, Incyte, CTI, Novartis, Sanofi and Shire. Dr Barbui received research grants and speaker fees from Novartis. Dr Marchetti’s research was funded by Janssen, Shire and Celgene; she received travel reimbursements from Janssen, Baxalta, Celgene and Shire and consultant or speaker fees from Gilead and Celgene. Dr Cervantes was a member of advisory boards for Novartis, Baxalta and AOP; he also joined speakers’ bureaus for Novartis, Baxalta and AOP. Dr Birgegård received research funding and speaker fees from Shire.<b>Author contributions</b>BT and MM conceived the project. All the authors contributed to the discussion on the PICOs and approved final recommendations. MM conducted the critical appraisal of the literature, tracked the feedbacks from the panelists and drafted the paper. All the authors revised the manuscript and approved the final version.